Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Bicycletx Limited currently manages 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 5 pending office actions are distributed across 5 distinct examiners and 4 distinct art units. This distribution indicates that while each case has a unique examiner, there is some overlap within the administrative art units. Such a spread suggests that the company's patent applications are being reviewed by a variety of individuals within a set of technical groups.
NIEBAUER, RONALD T is the busiest examiner for the company, with 1 pending office action currently assigned. Since there are 5 distinct examiners for the 5 pending office actions, the workload is evenly spread across the assigned personnel. The presence of 4 distinct art units for the portfolio suggests that the company's Biotechnology & Pharmaceuticals applications are diverse but share some commonality in classification. This requires a prosecution strategy that accounts for multiple examiner perspectives within the 4 distinct art units.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (40%) |
| Double-patenting + other | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
| MIKNIS, ZACHARY J | 1 | 68.6% | +32.2% |
| MYERS, CARLA J | 1 | 49.3% | +46.1% |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.6% |
| DABKOWSKI, ERINNE R | 1 | 55.9% | +69.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18001374 | TREATMENT OF DISEASES CHARACTERIZED BY OVEREXPRESSION OF ERYTHROPOIETIN-PRODUCING HEPATOCELLULAR RECEPTOR A2 (EPHA2) | PUTTLITZ, KARL J | 19d overdue |
| 17630747 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | DABKOWSKI, ERINNE R | 6d |
| 18021748 | BICYCLE CONJUGATES SPECIFIC FOR NECTIN-4 AND USES THEREOF | MYERS, CARLA J | 13d |
| 18796898 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 | NIEBAUER, RONALD T | — |
| 18271593 | METHODS FOR TREATING CANCER | MIKNIS, ZACHARY J | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| 1682 | 1 |
| 1646 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18796898 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 | NIEBAUER, RONALD T | 1658 | §103DP | Final Rejection | — | Pending | Aug 07, 2024 |
| 18271593 | METHODS FOR TREATING CANCER | MIKNIS, ZACHARY J | 1658 | §112DP | Non-Final OA | — | Pending | Jul 10, 2023 |
| 18021748 | BICYCLE CONJUGATES SPECIFIC FOR NECTIN-4 AND USES THEREOF | MYERS, CARLA J | 1682 | §112 | Final Rejection | 13d | Pending | Feb 16, 2023 |
| 18001374 | TREATMENT OF DISEASES CHARACTERIZED BY OVEREXPRESSION OF ERYTHROPOIETIN-PRODUCING HEPATOCELLULAR RECEPTOR A2 (EPHA2) | PUTTLITZ, KARL J | 1646 | §103§112DP | Final Rejection | 19d overdue | Pending | Dec 09, 2022 |
| 17630747 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | DABKOWSKI, ERINNE R | 1654 | §112 | Final Rejection | 6d | Pending | Jan 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial